AFP and hepatocellular carcinoma: Ramucirumab is a VEGFR2 antagonist that was FDA approved in 2019 as second-line therapy in patients with advanced HCC previously treated with sorafenib with an alpha fetoprotein (AFP) ≥ 400 ng/mL [12].